PR Newswire All News ReleasesQwen · 实盘不做把握 2/10不做原因:无增量信息
北京时间·🕒 发布 21:03:00·⟳ 抓取 21:03:21 +21s·⚡ 决策 08-31 21:13:59 +10m38s·57.4 天前
律所Wolf Haldenstein发布Aardvark Therapeutics证券集体诉讼征集公告，核心利空（III期试验暂停、股价暴跌56%）已发生6个月
该新闻稿是律所Wolf Haldenstein的证券集体诉讼客户征集广告（Attorney Advertising），不是公司新披露或新增负面事实。核心利空事件——Aardvark于2026年2月27日自愿暂停Phase 3 HERO试验——已发生约6个月，股价当时已暴跌56.2%至$5.47。集体诉讼的提起是该已知事件的常规法律后果，不提供任何关于公司基本面、药物管线或监管前景的新增信息。此外，AARD当前无法获取报价（no_price），标的可能已退市或丧失流动性，结构上不可交易。
📄 原文PR Newswire All News Releases↗ 原文
Lead Plaintiff Deadline October 13, 2026 NEW YORK and SAN DIEGO, Aug. 31, 2026 /PRNewswire/ -- Wolf Haldenstein Adler F…
不做 Aardvark Therapeutics（AARD.US）
①该新闻稿是律所获客广告，不是公司新披露或新增负面事实；②核心利空（III期HERO试验暂停、股价-56.2%）发生于2026年2月27日，已被市场消化6个月，无增量信息；③AARD报价不可获取（no_price），标的可能已退市或无流动性，结构上不可交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Wolf Haldenstein发布的新闻稿是典型的证券诉讼律所获客广告，描述的利空事件（ARD-101安全性问题导致III期HERO试验暂停、股价暴跌56%）发生在2026年2月底，距今已6个月。集体诉讼立案本身是已知负面事件的滞后法律程序，不构成新增催化。AARD报价不可获取，标的已不可交易。无新增事实、无可执行标的，判定不做。
🔎 新鲜度:最早出现 2026-08-31 · 扩散 low · price-in 风险 high ↗
先例如何影响了这次决策
对本次决策的影响:证券集体诉讼律所征集公告属于程序性滞后事件，历史上几乎不对股价产生增量影响；核心利空已在6个月前被市场定价。无需先例即判定不做。
方向:无先例可用
涨幅量级:无先例可用
形态:无先例可用
工具执行结果 · 成功 1 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 262 ms
{"result": "search_processed_events:agent query=`aard lawsuit wolf haldenstein | aardvark ard-101 trial pause | aardvark therapeutics securities class action`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.9/72 小时、1153 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - stock_quote 降级 stock_tools HTTP · 1,215 ms
取价失败: Futu returned no quote
原文全文
展开原文 · 3,011 字
Lead Plaintiff Deadline October 13, 2026
NEW YORK and SAN DIEGO, Aug. 31, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a nationally recognized securities litigation law firm, announces that a securities class action lawsuit has been filed in the announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) ("Aardvark" or the "Company"):
- common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's Initial Public Offering (the "IPO" or "Offering") conducted on or about February 13, 2025 and/or
- Aardvark securities between February 13, 2025, and May 14, 2026, both dates inclusive (the "Class Period").
Investors who purchased Aadvark shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for October 13, 2026.
The filed Complaint alleges that Defendants failed to disclose to investors that:
- ARD-101 was less safe than Defendants had led investors to believe;
- accordingly, ARD-101's clinical, regulatory, and commercial prospects were
overstated; and - as a result, Defendants' public statements were materially false and misleading at all relevant times.
It is alleged that the truth began to emerge on February 27, 2026, when Aardvark issued a press release "announc[ing] it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial." Aardvark attributed the decision to "reversible cardiac observations at above target therapeutic doses found during routine safety monitoring in a healthy volunteer study" and said that it "has voluntarily paused ongoing enrollment and dosing in the HERO trial" while "conducting a comprehensive review of the data to inform next steps."
On this news, Aardvark's stock price fell $7.02 per share, or 56.2%, to close at $5.47 per share on March 2, 2026.
This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven record of protecting the rights of investors.
We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.
There is no cost or obligation to speak with an attorney.
Contact:
- Phone: (800) 575-0735 or (212) 545-4774
- Email: [email protected]
- Contact Person: Gregory Stone, Director of Case and Financial Analysis
Firm Website: Wolf Haldenstein Adler Freeman & Herz LLP
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE Wolf Haldenstein Adler Freeman & Herz LLP
NEW YORK and SAN DIEGO, Aug. 31, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a nationally recognized securities litigation law firm, announces that a securities class action lawsuit has been filed in the announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) ("Aardvark" or the "Company"):
- common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's Initial Public Offering (the "IPO" or "Offering") conducted on or about February 13, 2025 and/or
- Aardvark securities between February 13, 2025, and May 14, 2026, both dates inclusive (the "Class Period").
Investors who purchased Aadvark shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for October 13, 2026.
The filed Complaint alleges that Defendants failed to disclose to investors that:
- ARD-101 was less safe than Defendants had led investors to believe;
- accordingly, ARD-101's clinical, regulatory, and commercial prospects were
overstated; and - as a result, Defendants' public statements were materially false and misleading at all relevant times.
It is alleged that the truth began to emerge on February 27, 2026, when Aardvark issued a press release "announc[ing] it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial." Aardvark attributed the decision to "reversible cardiac observations at above target therapeutic doses found during routine safety monitoring in a healthy volunteer study" and said that it "has voluntarily paused ongoing enrollment and dosing in the HERO trial" while "conducting a comprehensive review of the data to inform next steps."
On this news, Aardvark's stock price fell $7.02 per share, or 56.2%, to close at $5.47 per share on March 2, 2026.
This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven record of protecting the rights of investors.
We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.
There is no cost or obligation to speak with an attorney.
Contact:
- Phone: (800) 575-0735 or (212) 545-4774
- Email: [email protected]
- Contact Person: Gregory Stone, Director of Case and Financial Analysis
Firm Website: Wolf Haldenstein Adler Freeman & Herz LLP
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE Wolf Haldenstein Adler Freeman & Herz LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。